<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02043288</url>
  </required_header>
  <id_info>
    <org_study_id>NC-6004-005</org_study_id>
    <nct_id>NCT02043288</nct_id>
  </id_info>
  <brief_title>Combination Therapy With NC-6004 and Gemcitabine Versus Gemcitabine Alone in Pancreatic Cancer</brief_title>
  <official_title>A Phase III, Open-label, Randomized Study of the Combination Therapy With NC-6004 and Gemcitabine Versus Gemcitabine Alone in Patients With Locally Advanced or Metastatic Pancreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Orient Europharma Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>NanoCarrier Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Orient Europharma Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical trial is designed to evaluate the impact of the addition of NC-6004 to
      gemcitabine in the treatment of patients with locally advanced or metastatic pancreatic
      cancer in Asian countires.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pancreatic cancer is one of the most deadly cancers because of the predominately late
      diagnosis. Gemcitabine (GEM) is the standard treatment for advanced and metastatic pancreatic
      cancer. According to preclinical data and few early phase studies, a combined use of
      gemcitabine and cisplatin (CDDP) showed synergistic efficacy against pancreatic cancer.
      NC-6004, a novel micellar cisplatin formulation, retains the activity but avoids the renal
      toxicity and neurotoxicity caused by the high peak Cmax concentrations of cisplatin. This
      trial is designed to evaluate the impact of the addition of NC-6004 to gemcitabine in the
      treatment of patients with locally advanced or metastatic pancreatic cancer.

      The main hypothesis of this study is that NC-6004 plus gemcitabine combination is superior to
      gemcitabine alone in terms of overall survival in locally advanced or metastatic pancreatic
      cancer patients
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">March 2018</completion_date>
  <primary_completion_date type="Anticipated">March 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>3.5 years</time_frame>
    <description>Overall survival is defined as the time from the treatment initiation until death from any cause, and censored at the last follow up time.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>3.5 years</time_frame>
    <description>Progression free survival is defined as the time from the treatment initiation until progression or death, and censored at the last follow up time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate (RR) and disease control rate (DCR) according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 criteria</measure>
    <time_frame>3.5 years</time_frame>
    <description>Response rate is defined as counts and proportions of patients responding complete response or partial response within the duration of the study.
Disease control rate is defined as counts and proportions of patients responding complete response, partial response or progressive disease within the duration of the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>3.5 years</time_frame>
    <description>Duration of overall response (DOR) will be measured from the time of initial response (CR or PR) until documented progression or death, and censored at last follow up time.
Duration of stable disease (DSD) will be measured from the time of initial stable disease (SD) until documented progression or death, and censored at last follow up time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CA19-9</measure>
    <time_frame>3.5 years</time_frame>
    <description>CA19-9 values and changes from baseline will be summarized.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life (QoL) using EORTC QLQ-C30</measure>
    <time_frame>3.5 years</time_frame>
    <description>Quality of life (QoL) values and changes from baseline will be summarized.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>exploratory objective</measure>
    <time_frame>3.5 years</time_frame>
    <description>Pharmacokinetic profile , such as Cmax, Tmax, T1/2 and AUC</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Pancreatic Neoplasms</condition>
  <arm_group>
    <arm_group_label>NC-6004 and Gemcitabine combination</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>90mg/m2 i.v. on Day 1 and 1000mg/m2 i.v. on Day 1, 8 and 15 respectively</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gemcitabine monotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1000mg/m2 i.v. on Day 1 ,8 and 15</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NC-6004</intervention_name>
    <description>Study group (3 week/cycle):
NC-6004 90 mg/m2 i.v. inf. over 60 min on Day 1</description>
    <arm_group_label>NC-6004 and Gemcitabine combination</arm_group_label>
    <other_name>Micelplatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>Study group (3 week/cycle):
Gemcitabine 1000 mg/m2 i.v. inf. over 30 min on Day 1 and Day 8 (follow by administration of NC-6004)
Control group (4 week/cycle):
Gemcitabine 1000 mg/m2 i.v. inf. over 30 min on Day 1, Day 8 and Day 15</description>
    <arm_group_label>NC-6004 and Gemcitabine combination</arm_group_label>
    <arm_group_label>Gemcitabine monotherapy</arm_group_label>
    <other_name>Gemzar</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female aged between 20 to 80 years (inclusive)

          2. Unresectable, histologically or cytologically confirmed, locally advanced or
             metastatic pancreatic cancer (adenocarcinoma, adenosquamous carcinoma or poorly
             differentiated carcinoma)

          3. Presence of at least one measurable tumor lesion (longest diameter ≥ 10 mm)

          4. No prior systemic anti-cancer therapy and radiotherapy for advanced pancreatic cancer

          5. Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 1

          6. Adequate organ function defined as:

               -  3,000 cells/μL ≤ White blood cell count (WBC) ≤ 12,000 cells/μL

               -  Absolute neutrophils count (ANC) ≥ 1,500 cells/μL

               -  Platelets ≥ 100,000 cells/μL

               -  Hemoglobin (Hb) ≥ 9.0 g/dL

               -  Alanine amino transferase (ALT) and aspartate amino transferase (AST) ≤ 2.5 times
                  the upper limit of normal (ULN) in patients with no demonstrable hepatic
                  metastasis, or ≤ 5 x ULN in patients with hepatic metastasis

               -  Serum bilirubin ≤ 1.5 x ULN in patients with no demonstrable hepatic metastasis
                  and obstructive jaundice, or ≤ 2.5 x ULN in patients with hepatic metastasis or
                  obstructive jaundice

               -  Serum creatinine (SCr) ≤ 1.5 mg/dL and creatinine clearance (CrCl) ≥ 60 mL/min
                  (from 24-hour urine test or Cockcroft-Gault formula)

               -  Corrected serum calcium ≤ ULN

          7. If fertile, willing to use barrier contraception till 6 months after the end of
             treatment

          8. Willing and able to comply with study procedures and provide written informed consent

        Exclusion Criteria:

          1. Pregnancy or breastfeeding

          2. Active concomitant malignancy or history of other cancer except carcinoma in situ of
             cervical squamous cell carcinoma, stage I colon cancer or other malignance that has
             remained disease-free for more than 3 years after curative intervention

          3. Metastasis to the central nervous system or brain

          4. Evidence of hearing impaired ≥ Grade 2 as assessed by pure tone audiometry or other
             neurotoxicity ≥ Grade 2

          5. Pulmonary fibrosis or interstitial pneumonia

          6. Marked pleural effusion or ascites above Grade 2

          7. Patient with known HIV infection

          8. Patient with active hepatitis B, hepatitis C or any other ongoing severe infections

          9. Severe mental disorder

         10. As judged by the investigator, any evidence of significant laboratory findings or
             severe/uncontrolled clinical disorders (e.g. dementia, myocardial infarction within 6
             months prior to enrollment, New York Heart Association (NYHA) Class III or IV heart
             failure, unstable angina, active cardiomyopathy, unstable arrhythmia, and other
             unstable or uncompensated respiratory, cardiac, hepatic, renal and/or infectious
             disease)

         11. Patient with known hypersensitivity to Pt compounds

         12. Known severe drug hypersensitivity

         13. Treatment with a non-approved or investigational product within 30 days before Day 1
             of study treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Li-Tzong Chen, M.D., Ph. D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute of Cancer Research, National Health Research Institutes</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>I-Chan Lee, COM</last_name>
    <phone>+886-2-27554881</phone>
    <phone_ext>2928</phone_ext>
    <email>IChan.lee@oppharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Queen Mary Hospital</name>
      <address>
        <city>Hong Kong Island</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Prince of Wales Hospital</name>
      <address>
        <city>New territories</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Aichi Cancer Center</name>
      <address>
        <city>Aichi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chiba Cancer Center</name>
      <address>
        <city>Chiba</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hokkaido University Hospital</name>
      <address>
        <city>Hokkaido</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Kyushu Cancer Center</name>
      <address>
        <city>Kyushu</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Osaka National Hospital</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Osaka Medical Center for Cancer and Cardiovascular Diseases</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Saitama Cancer Center</name>
      <address>
        <city>Saitama</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Shikoku Cancer Center</name>
      <address>
        <city>Shikoku</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Shizuoka Cancer Center</name>
      <address>
        <city>Shizuoka</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Center Hospital of the National Center for Global Health and Medicine</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kyorin university Hospital</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Hospital East</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Hospital</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Cancer Institute Hospital of JFCR</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The University of Tokyo Hospital</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kanagawa Cancer Center</name>
      <address>
        <city>Yokohama</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ajou University Hospital (AUH)</name>
      <address>
        <city>Gyeonggi-do</city>
        <zip>443-380</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hyun Woo Lee, MD PhD</last_name>
      <phone>+82-31-219-5989</phone>
      <email>hwlee71@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center (SMC)</name>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Suk Park Young, MD PhD</last_name>
      <phone>+82-2-3410-3459</phone>
      <email>pys27hmo@skku.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Catholic University of Korea, Seoul St. Mary's Hospital (CUK SSMH)</name>
      <address>
        <city>Seoul</city>
        <zip>137-701</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Myung-Ah Lee, MD PhD</last_name>
      <phone>+82-2-2258-6044</phone>
      <email>angelamd@catholic.ac.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Korea University Guro Hospital (KUGH)</name>
      <address>
        <city>Seoul</city>
        <zip>152-703</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Suk Kim Jun, MD PhD</last_name>
      <phone>+82-2-2626-3057</phone>
      <email>kjs6651@kumc.or.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yonsei University Health System, Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>50-1</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jin Choi Hye, MD PhD</last_name>
      <phone>+82-2-2228-8133</phone>
      <phone_ext>2227</phone_ext>
      <email>eunkyung@yuhs.ac</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Sultan Ismail</name>
      <address>
        <city>Johor Bahru</city>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Kuala Lumpur</name>
      <address>
        <city>Kuala Lumpur</city>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Philippine General Hospital</name>
      <address>
        <city>Ermita Manila</city>
        <country>Philippines</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Makati Medical Center</name>
      <address>
        <city>Makati</city>
        <zip>1229</zip>
        <country>Philippines</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary Jane, MD PhD</last_name>
      <phone>888-8999</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Lukes Medical Center</name>
      <address>
        <city>Quezon</city>
        <country>Philippines</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>National University Hospital</name>
      <address>
        <city>Singapore</city>
        <zip>119074</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>National Cancer Centre</name>
      <address>
        <city>Singapore</city>
        <zip>169610</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chiayi Chang Gung Memorial Hospital</name>
      <address>
        <city>Chiayi</city>
        <zip>61363</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cih-En Huang, MD PhD</last_name>
      <phone>+886-5-3621000</phone>
      <phone_ext>2106</phone_ext>
      <email>dnacihen@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kaohsiung Medical University Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <zip>80756</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ta-Chih Liu, MD PhD</last_name>
      <phone>+886-7-312-1101</phone>
      <phone_ext>6113</phone_ext>
      <email>d730093@cc.kmu.edu.tw</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chang Gung Memorial Hospital, Kaohsiung Branch</name>
      <address>
        <city>Kaohsiung</city>
        <zip>833</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>China Medical University Hospital</name>
      <address>
        <city>Taichung</city>
        <zip>404</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Taichung Veterans General Hospital</name>
      <address>
        <city>Taichung</city>
        <zip>40750</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Cheng Kung University Hospital</name>
      <address>
        <city>Tainan</city>
        <zip>704</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chi Mei Hospital</name>
      <address>
        <city>Tainan</city>
        <zip>710</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mackay Memorial Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>104</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>106</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Taipei Medical University Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>110</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Koo Foundation Sun Yat-Sen Cancer Center</name>
      <address>
        <city>Taipei</city>
        <zip>112</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hsin-Hsuan Chen, MD PhD</last_name>
      <phone>+886-935-303-335</phone>
      <email>hsinhsuanchen@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Taipei Veterans General Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>112</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tri-Service General Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>114</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Taipei Medical University-Shuang-Ho Hospital, Ministry of Health and Welfare</name>
      <address>
        <city>Taipei</city>
        <zip>235</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chang Gung Memorial Hospital, Linkou Branch</name>
      <address>
        <city>Taipei</city>
        <zip>333</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chi Mei Medical Center</name>
      <address>
        <city>Yongkang</city>
        <zip>710</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yin-Hsun Feng, MD PhD</last_name>
      <phone>+886-6-281-2811</phone>
      <phone_ext>57266</phone_ext>
      <email>yinhsun.feng@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Hong Kong</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Malaysia</country>
    <country>Philippines</country>
    <country>Singapore</country>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 14, 2014</study_first_submitted>
  <study_first_submitted_qc>January 21, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 23, 2014</study_first_posted>
  <last_update_submitted>November 13, 2016</last_update_submitted>
  <last_update_submitted_qc>November 13, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 15, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pancreatic cancer</keyword>
  <keyword>Platinum</keyword>
  <keyword>Micelle</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

